Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Emmy M Dolman

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2013
Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumoursLaurel T Bate-Eya, Marli E Ebus, Jan Koster, et al.
Journal of the American Society of Nephrology : JASN|February 11, 2014
Epac-Rap signaling reduces oxidative stress in the tubular epitheliumGeurt Stokman, Yu Qin, Tijmen H Booij, et al.
Biomedicines|March 25, 2022
High-Throughput Drug Library Screening in Primary <i>KMT2A</i>-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 SignalingPriscilla Wander, Susan T C J M Arentsen-Peters, Kirsten S Vrenken, et al.
NPJ Precision Oncology|May 10, 2025
A novel TRKB-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activationLauren M Brown, Gabor Tax, Pablo Acera Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Molecular Cancer Therapeutics|April 14, 2021
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma CellsLindy Vernooij, Laurel T Bate-Eya, Lindy K Alles, et al.
Journal of Medicinal Chemistry|November 18, 2025
Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in NeuroblastomaSimon Krols, Muhammad Rishfi, Fien Martens, et al.
Frontiers in Oncology|October 14, 2022
Chromosome 11q loss and <i>MYCN</i> amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastomaKaylee M Keller, Thomas F Eleveld, Linda Schild, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2021
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignanciesKaylee M Keller, Sonja Krausert, Apurva Gopisetty, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Oncotarget|April 9, 2016
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionLaurel T Bate-Eya, Ilona J M den Hartog, Ida van der Ploeg, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2013
Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumoursLaurel T Bate-Eya, Marli E Ebus, Jan Koster, et al.
Journal of the American Society of Nephrology : JASN|February 11, 2014
Epac-Rap signaling reduces oxidative stress in the tubular epitheliumGeurt Stokman, Yu Qin, Tijmen H Booij, et al.
Biomedicines|March 25, 2022
High-Throughput Drug Library Screening in Primary <i>KMT2A</i>-Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 SignalingPriscilla Wander, Susan T C J M Arentsen-Peters, Kirsten S Vrenken, et al.
NPJ Precision Oncology|May 10, 2025
A novel TRKB-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activationLauren M Brown, Gabor Tax, Pablo Acera Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Molecular Cancer Therapeutics|April 14, 2021
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma CellsLindy Vernooij, Laurel T Bate-Eya, Lindy K Alles, et al.
Journal of Medicinal Chemistry|November 18, 2025
Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in NeuroblastomaSimon Krols, Muhammad Rishfi, Fien Martens, et al.
Frontiers in Oncology|October 14, 2022
Chromosome 11q loss and <i>MYCN</i> amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastomaKaylee M Keller, Thomas F Eleveld, Linda Schild, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2021
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignanciesKaylee M Keller, Sonja Krausert, Apurva Gopisetty, et al.
Pageof 4